Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Selecta Biosciences Inc is a biotechnology business based in the US. Selecta Biosciences shares (SELB) are listed on the NASDAQ and all prices are listed in US Dollars. Selecta Biosciences employs 43 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.27|
|52-week range||$2.17 - $5.70|
|50-day moving average||$4.32|
|200-day moving average||$4.02|
|Wall St. target price||$8.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.41|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-12)||-1.61%|
|1 month (2021-09-17)||-4.04%|
|3 months (2021-07-19)||16.99%|
|6 months (2021-04-19)||12.07%|
|1 year (2020-10-19)||87.28%|
|2 years (2019-10-18)||200.70%|
|3 years (2018-10-19)||13.81|
|5 years (2016-10-19)||17.36|
|Revenue TTM||$47.3 million|
|Gross profit TTM||$-37,908,000|
|Return on assets TTM||-13.85%|
|Return on equity TTM||0%|
|Market capitalisation||$491.4 million|
TTM: trailing 12 months
There are currently 7.3 million Selecta Biosciences shares held short by investors – that's known as Selecta Biosciences's "short interest". This figure is 9.7% up from 6.6 million last month.
There are a few different ways that this level of interest in shorting Selecta Biosciences shares can be evaluated.
Selecta Biosciences's "short interest ratio" (SIR) is the quantity of Selecta Biosciences shares currently shorted divided by the average quantity of Selecta Biosciences shares traded daily (recently around 918616.49874055). Selecta Biosciences's SIR currently stands at 7.94. In other words for every 100,000 Selecta Biosciences shares traded daily on the market, roughly 7940 shares are currently held short.
However Selecta Biosciences's short interest can also be evaluated against the total number of Selecta Biosciences shares, or, against the total number of tradable Selecta Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Selecta Biosciences's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Selecta Biosciences shares in existence, roughly 60 shares are currently held short) or 0.0888% of the tradable shares (for every 100,000 tradable Selecta Biosciences shares, roughly 89 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Selecta Biosciences.
Find out more about how you can short Selecta Biosciences stock.
We're not expecting Selecta Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Selecta Biosciences's shares have ranged in value from as little as $2.17 up to $5.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Selecta Biosciences's is 1.0291. This would suggest that Selecta Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.